Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
Targets |
Lipopeptide HSV-1 HSV-2
|
---|---|
ln Vitro |
In vitro, surfactin can boost NSC277174's effectiveness against avian pathogenic Escherichia coli (APEC) using antimicrobial assays including fractional inhibitory concentration (FIC) and minimum inhibitory concentration (MIC). The minimum inhibitory concentrations of NSC277174 and surfactin for the APEC O78 strain are 1000 ug/ml and >1 mg/ml, respectively[1].
|
ln Vivo |
Surfactin and NSC277174 work together to reduce the number of deaths and liver bacterial burdens in the chick infection model (E. coli inoculation) while also controlling the expression of inflammatory cytokines and other factors. When combined with NSC277174, surfactin can function as a new antibacterial adjuvant to prevent AEPC infection in chickens[1].
|
References |
|
Additional Infomation |
Surfactin C is a cyclodepsipeptide that is N-[(3R)-3-hydroxy-13-methyltetradecanoyl]-L-alpha-glutamyl-L-leucyl-D-leucyl-L-valyl-L-alpha-aspartyl-D-leucyl-L-leucine in which the C-terminal carboxy group has been lactonised by condensation with the alcoholic hydroxy group. It has a role as an antibacterial agent, an antifungal agent, an antiviral agent, a surfactant, a metabolite, an antineoplastic agent and a platelet aggregation inhibitor. It is a cyclodepsipeptide, a lipopeptide antibiotic and a macrocyclic lactone.
Surfactin has been reported in Bacillus subtilis, Bacillus mojavensis, and Bacillus thuringiensis with data available. See also: Surfactin peptide (annotation moved to). |
Molecular Formula |
C53H93N7O13
|
---|---|
Molecular Weight |
1036.34463572502
|
Exact Mass |
1035.683
|
CAS # |
252023-70-4
|
PubChem CID |
443592
|
Appearance |
White to off-white solid powder
|
LogP |
8.8
|
Hydrogen Bond Donor Count |
9
|
Hydrogen Bond Acceptor Count |
13
|
Rotatable Bond Count |
24
|
Heavy Atom Count |
73
|
Complexity |
1800
|
Defined Atom Stereocenter Count |
8
|
SMILES |
O1C([C@H](CC(C)C)NC([C@@H](CC(C)C)NC([C@H](CC(=O)O)NC([C@H](C(C)C)NC([C@@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCC(=O)O)NC(C[C@H]1CCCCCCCCCC(C)C)=O)=O)=O)=O)=O)=O)=O)=O
|
InChi Key |
NJGWOFRZMQRKHT-WGVNQGGSSA-N
|
InChi Code |
InChI=1S/C53H93N7O13/c1-30(2)20-18-16-14-13-15-17-19-21-36-28-43(61)54-37(22-23-44(62)63)47(66)55-38(24-31(3)4)48(67)57-40(26-33(7)8)51(70)60-46(35(11)12)52(71)58-41(29-45(64)65)50(69)56-39(25-32(5)6)49(68)59-42(27-34(9)10)53(72)73-36/h30-42,46H,13-29H2,1-12H3,(H,54,61)(H,55,66)(H,56,69)(H,57,67)(H,58,71)(H,59,68)(H,60,70)(H,62,63)(H,64,65)/t36-,37+,38+,39-,40-,41+,42+,46+/m1/s1
|
Chemical Name |
3-[(3S,6R,9S,12S,15R,18S,21S,25R)-9-(carboxymethyl)-3,6,15,18-tetrakis(2-methylpropyl)-25-(10-methylundecyl)-2,5,8,11,14,17,20,23-octaoxo-12-propan-2-yl-1-oxa-4,7,10,13,16,19,22-heptazacyclopentacos-21-yl]propanoic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 50 mg/mL H2O : 31.25 mg/mL
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 110 mg/mL (Infinity mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.9649 mL | 4.8246 mL | 9.6492 mL | |
5 mM | 0.1930 mL | 0.9649 mL | 1.9298 mL | |
10 mM | 0.0965 mL | 0.4825 mL | 0.9649 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.